iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age : a REALI pooled analysis of prospective real-world data
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083855" target="_blank" >RIV/00023001:_____/23:00083855 - isvavai.cz</a>
Result on the web
<a href="https://dom-pubs.pericles-prod.literatumonline.com/doi/epdf/10.1111/dom.15027" target="_blank" >https://dom-pubs.pericles-prod.literatumonline.com/doi/epdf/10.1111/dom.15027</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/dom.15027" target="_blank" >10.1111/dom.15027</a>
Alternative languages
Result language
angličtina
Original language name
iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age : a REALI pooled analysis of prospective real-world data
Original language description
Aim: To evaluate the effectiveness and safety in routine clinical practice of insulin glargine/lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) according to age.Methods: Patient-level data were pooled from 1316 adults with T2D inadequately controlled on oral antidiabetic drugs with or without basal insulin who initiated iGlarLixi for 24 weeks. Participants were classified into age subgroups of younger than 65 years (N = 806) and 65 years or older (N = 510).Results: Compared with participants aged younger than 65 years, those aged 65 years or older had a numerically lower mean body mass index (31.6 vs. 32.6 kg/m(2)), a longer median diabetes duration (11.0 vs. 8.0 years), were more likely to receive prior basal insulin (48.4% vs. 43.5%) and had a lower mean HbA1c (8.93% [74.10 mmol/mol] vs. 9.22% [77.28 mmol/mol]). Similar and clinically relevant reductions in HbA1c and fasting plasma glucose from baseline to week 24 of iGlarLixi therapy were observed regardless of age. At 24 weeks, least-squares adjusted mean (95% confidence interval [CI]) change in HbA1c from baseline was -1.55% (-1.65% to -1.44%) in those aged 65 years or older and -1.42% (-1.50% to -1.33%) in those aged younger than 65 years (95% CI: -0.26% to 0.00%; P = .058 between subgroups). Low incidences of gastrointestinal adverse events and hypoglycaemic episodes were reported in both age subgroups. iGlarLixi decreased mean body weight from baseline to week 24 in both subgroups (-1.6 kg in those aged = 65 years and -2.0 kg in those aged < 65 years).Conclusions: iGlarLixi is effective and well tolerated in both younger and older people with uncontrolled T2D.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Diabetes, obesity and metabolism
ISSN
1462-8902
e-ISSN
1463-1326
Volume of the periodical
25
Issue of the periodical within the volume
6
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
1723-1730
UT code for WoS article
000957166100001
EID of the result in the Scopus database
2-s2.0-85150890106